US Spec. Ops. Command to test "anti-aging" pill within a year

Army General Richard D. Clarke, commander U.S. Special Operations Command, addresses the annual Special Operations Forces Industry Conference being held virtually from SOFWERX in Tampa, Fla., May 17-21, 2021. SOFIC is the premiere virtual conference for the SOF community to interact with industry and to collaborate on the challenges, initiatives and way-ahead in delivering the most cutting-edge capabilities into the hands of SOF operators. (Photo by U.S. Air Force Master Sgt. Barry Loo)

The US Special Operations Command are working on a medication that will prevent rapid age and decline in thier operators.

The “anti-aging” pill will begin clinical trials in 2021, and is believed to reduce some of the issues the Pentagon has with more experienced operators sustaining breakdown and injury due to age.

The new medication “has the potential, if it is successful, to truly delay aging, truly prevent onset of injury — which is just amazingly game changing,” Lisa Sanders, director of science and technology for Special Operations Forces, acquisition, technology & logistics (SOF AT&L).

SOCOM rep Commander Tim Hawkins, US Navy, told Breaking Defense that pre-clinical safety and dosing studies have already been completed.

“We have completed pre-clinical safety and dosing studies in anticipation of follow-on performance testing in fiscal year 2022,” he said.

Little is known about the pill, though it it known that biotechnology plays a major role.

SOCOM has “stayed out of long-term genetic engineering- that makes people very very uncomfortable,” Sanders said, “but there’s a huge commercial marketplace for things that can avoid injury, that can slow down aging, that can improve sleep.”

The content of this webpage may not be reproduced or used in any manner whatsoever without the express written consent of Bright Mountain Media, Inc. which may be contacted at info@brightmountainmedia.com, ticker BMTM.

Post navigation